- Home
- AUR vs MRNA Comparison
AUR vs MRNA Comparison
Compare AUR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUR | MRNA |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.3B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | AUR | MRNA |
|---|---|---|
| Price | $4.38 | $29.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 14 |
| Target Price | $10.06 | ★ $33.25 |
| AVG Volume (30 Days) | ★ 15.3M | 9.8M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,000,000.00 | ★ $2,232,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $939.88 | $0.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $22.28 |
| 52 Week High | $10.77 | $48.92 |
Technical Indicators
Market Signals| Indicator | AUR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 65.99 |
| Support Level | $3.97 | $26.90 |
| Resistance Level | $4.67 | $26.00 |
| Average True Range (ATR) | 0.21 | 1.14 |
| MACD | 0.09 | 0.59 |
| Stochastic Oscillator | 67.74 | 85.99 |
Price Performance
Historical ComparisonAbout AUR Aurora Innovation Inc.
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.